Eli Lilly and Company (LLY)

$929.55 -9.92 (-1.06%)
Market Cap 887.63B
Revenue (ttm) 65.18B
Net Income (ttm) 20.64B
EPS (ttm) N/A
PE Ratio 39.45
Forward PE 27.55
Profit Margin 31.67%
Debt to Equity Ratio 1.54
Volume 2,089,500
Avg Vol 3,195,192
Day's Range N/A - N/A
Shares Out 944.82M
Stochastic %K 44%
Beta 0.51
Analysts Strong Sell
Price Target $1,239.50

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
howardlindzon
howardlindzon Apr. 14 at 3:24 PM
$LLY GLP's are just a miracle ...hope It stays that way
0 · Reply
EdwardGonza
EdwardGonza Apr. 14 at 2:56 PM
$AMZN $MRK $VOYG $LLY $NVO | AWS launches Amazon Bio Discovery, a no code AI platform for drug dev. Bayer and MSK are already using it to cut antibody design from 1 year to weeks. Amazon is now the primary compute layer for the $200B AI driven pharmaceutical pipeline.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 14 at 2:42 PM
$LEXX $LLY just bout a biotech for $300M. Eli Lilly has agreed to pay up to $300 million for pre-clinical biotechnology company CrossBridge Bio in a deal that bolsters the drugmaker's cancer pipeline. The purchase price includes an undisclosed upfront payment, along with a potential milestone payment, CrossBridge said Tuesday. Houston -based CrossBridge is developing dual-payload antibody-drug conjugates, or ADCs, with its lead candidate expected to enter clinical studies later this year. THIS CAN HAPPEN TO $LEXX IN THE BLINK OF ANY EYE, BUT IMO HECK OF ALOT MORE THAN $300M. Even $300M buyout would put the price 15X from here valuation wise. Do the math.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 14 at 2:25 PM
$LEXX there is no resistance, charts dont mean anything. When positive news hits this runs faster than a gazelle. Also, did you see the news from FDA regulatory update this morning on $NVO $LLY ******The FDA just confirmed the exact weakness Lexaria is trying to fix. Clock is ticking. ⏰ Important regulatory update for Lilly’s new obesity pill Foundayo. According to an FDA letter, Eli Lilly has been asked to provide additional post-marketing safety data, including further assessment of potential liver injury. The FDA is also requiring studies on: • cardiovascular risk • delayed gastric emptying • drug levels in breast milk during lactation This does not change the approval status, but it means the safety profile will remain under close regulatory review as the launch continues.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 14 at 2:01 PM
Eli Lilly To Acquire CrossBridge Bio To Advance Dual-Payload Cancer Drugs $LLY https://stocktwits.com/news/equity/markets/eli-lilly-to-acquire-crossbridge-bio/cZJq4CiRIHo
0 · Reply
moneybag888
moneybag888 Apr. 14 at 1:58 PM
$MGTX $LLY we need volume please $ROOT $CAR $GSAT
0 · Reply
TrustButVerifi
TrustButVerifi Apr. 14 at 1:56 PM
$VKTX Maybe now that NVO partnered with OpenAi, artificial intelligence will prevail over Stupidity and they pay $40 Billion for VKTX not to lose $400 Billion! smh! $LLY $NVO
0 · Reply
mbar5
mbar5 Apr. 14 at 1:30 PM
$LLY going down hard today
0 · Reply
wwmeinc
wwmeinc Apr. 14 at 1:23 PM
$VKTX $LLY $NVO $JNJ $ABBV ......KLRA's S-1 released...looking for a $14-$16 IPO price but not set in stone yet...14 M shares maybe...or more...looks like they are planning on this upcoming Friday as a trading start...money coming to our sector.....helps in keeping our name on top to my eyes....but that is just my opinion...glta https://www.iposcoop.com/the-ipo-buzz-obesity-focused-kailera-therapeutics-sets-500-million-ipo/
1 · Reply
dewmoore
dewmoore Apr. 14 at 12:41 PM
$SLS MUST READ: The year-long "Cancer Calculus" investigation was a year-long investigation ( 124 journalists 48 newsrooms 37 countries. It's the ultimate $SLS bull case. It exposes $MRK 's DESPERATION & patent games (1,212 patent applications) designed to keep prices high. Merck needs $SLS and fresh PATENTS to survive—or $LLY or $PFE will buy $SLS to end $MRK $31B in revenue. A buyer like $LLY or $PFE could create a NEW Super-Drug patent by COMBINING $SLS proprietary assets with GENERIC Keytruda in 2028 LEGALLY BLOCKING generic rivals from the BEST cocktails. Trump & RFK Jr. want cost-effective cures. Vaccines like GPS are the answer. With $SLS- 009 targeting 20+ mutations where blockbusters fail, the urgency is at an all-time high. A bidding war is the only logical conclusion. A $31B valuation for $SLS (matching Keytruda's annual haul) puts the stock at $172.67/share. Spending $31B to protect a $300B revenue stream over 10 years is "SMART as F*CK" https://www.icij.org/investigations/cancer-calculus/merck-keytruda-cancer-drug-price/
0 · Reply
Latest News on LLY
LLY Stock To $2,000?

Apr 14, 2026, 10:36 AM EDT - 1 hour ago

LLY Stock To $2,000?

Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company

Apr 14, 2026, 9:00 AM EDT - 2 hours ago

Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

Apr 14, 2026, 8:00 AM EDT - 3 hours ago

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

Apr 13, 2026, 6:45 AM EDT - 1 day ago

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

LLY v. NVO: Weighing Who's Winning the GLP-1 Industry

Apr 12, 2026, 9:30 AM EDT - 2 days ago

LLY v. NVO: Weighing Who's Winning the GLP-1 Industry

NVO

Genetic variations linked to weight loss, side effects from GLP-1 drugs

Apr 10, 2026, 4:07 PM EDT - 3 days ago

Genetic variations linked to weight loss, side effects from GLP-1 drugs

NVO

Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

Apr 10, 2026, 2:38 AM EDT - 4 days ago

Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India

NVO

Eli Lilly's Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock.

Apr 9, 2026, 1:27 PM EDT - 4 days ago

Eli Lilly's Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock.

Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery

Apr 9, 2026, 7:38 AM EDT - 5 days ago

Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery

AMZN

Eli Lilly Weight-Loss Pill Becomes Available in U.S.

Apr 9, 2026, 7:13 AM EDT - 5 days ago

Eli Lilly Weight-Loss Pill Becomes Available in U.S.

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

Apr 9, 2026, 6:45 AM EDT - 5 days ago

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation

Apr 2, 2026, 9:01 PM EDT - 11 days ago

India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation

A new weight-loss pill is here, and it could reshape the GLP-1 market

Apr 2, 2026, 4:07 PM EDT - 11 days ago

A new weight-loss pill is here, and it could reshape the GLP-1 market

MSFT, AVGO, LLY & Other Stock Market Opportunities Amid U.S.-Iran War

Apr 2, 2026, 3:30 PM EDT - 11 days ago

MSFT, AVGO, LLY & Other Stock Market Opportunities Amid U.S.-Iran War

AVGO MSFT

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 12 days ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO PFE

Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh

Apr 2, 2026, 9:34 AM EDT - 12 days ago

Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh

Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison

Apr 2, 2026, 8:00 AM EDT - 12 days ago

Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison

NVO

Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead

Apr 2, 2026, 7:28 AM EDT - 12 days ago

Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead

NVO

Novo VP Weighs In on Approval of Lilly's Obesity Pill

Apr 1, 2026, 5:14 PM EDT - 12 days ago

Novo VP Weighs In on Approval of Lilly's Obesity Pill

NVO

Pricing and availability of Novo, Lilly's weight-loss drugs

Apr 1, 2026, 3:07 PM EDT - 12 days ago

Pricing and availability of Novo, Lilly's weight-loss drugs

NVO

Lilly gains after FDA approves weight-loss pill, sizing down investor doubts

Apr 1, 2026, 2:21 PM EDT - 12 days ago

Lilly gains after FDA approves weight-loss pill, sizing down investor doubts

VIEW Lilly gets FDA nod for oral obesity pill, analysts see strong uptake potential

Apr 1, 2026, 2:09 PM EDT - 12 days ago

VIEW Lilly gets FDA nod for oral obesity pill, analysts see strong uptake potential

Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says

Apr 1, 2026, 1:32 PM EDT - 12 days ago

Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says

FDA Approves Eli Lilly's Weight Loss Pill—Second Weight GLP-1 Drug In Pill Form

Apr 1, 2026, 12:50 PM EDT - 12 days ago

FDA Approves Eli Lilly's Weight Loss Pill—Second Weight GLP-1 Drug In Pill Form

America has a new weight-loss drug, and it's a pill

Apr 1, 2026, 12:32 PM EDT - 12 days ago

America has a new weight-loss drug, and it's a pill

Eli Lilly CEO: Our pill supply can 'reach the planet'

Apr 1, 2026, 12:09 PM EDT - 12 days ago

Eli Lilly CEO: Our pill supply can 'reach the planet'

Eli Lilly Stock Jumps. A Weight-Loss Pill Is Officially on the Market.

Apr 1, 2026, 11:50 AM EDT - 12 days ago

Eli Lilly Stock Jumps. A Weight-Loss Pill Is Officially on the Market.

Lilly's weight-loss pill wins US approval

Apr 1, 2026, 11:41 AM EDT - 12 days ago

Lilly's weight-loss pill wins US approval

The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market

Apr 1, 2026, 11:38 AM EDT - 13 days ago

The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market

Cramer's Mad Dash -- Eli Lilly

Apr 1, 2026, 11:31 AM EDT - 13 days ago

Cramer's Mad Dash -- Eli Lilly

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

Apr 1, 2026, 11:30 AM EDT - 13 days ago

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market

Apr 1, 2026, 11:28 AM EDT - 13 days ago

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market

Stock Of The Day: Where Will Eli Lilly Turn?

Apr 1, 2026, 9:50 AM EDT - 13 days ago

Stock Of The Day: Where Will Eli Lilly Turn?

Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly

Mar 31, 2026, 7:43 PM EDT - 13 days ago

Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly

CNTA

Lilly and Novo Show How AI Is Rewiring Big Pharma

Mar 31, 2026, 2:45 PM EDT - 13 days ago

Lilly and Novo Show How AI Is Rewiring Big Pharma

NVO

Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs

Mar 31, 2026, 12:24 PM EDT - 13 days ago

Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs

CNTA

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Mar 31, 2026, 10:46 AM EDT - 14 days ago

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

CNTA

Why Eli Lilly Is Buying Centessa for $7.8 Billion

Mar 31, 2026, 10:27 AM EDT - 14 days ago

Why Eli Lilly Is Buying Centessa for $7.8 Billion

CNTA

Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug

Mar 31, 2026, 8:32 AM EDT - 14 days ago

Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

Mar 31, 2026, 7:39 AM EDT - 14 days ago

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

NVO

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion

Mar 31, 2026, 7:18 AM EDT - 14 days ago

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion

CNTA

Eli Lilly to buy Centessa Pharma in $6.3 billion deal

Mar 31, 2026, 6:53 AM EDT - 14 days ago

Eli Lilly to buy Centessa Pharma in $6.3 billion deal

CNTA

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Mar 31, 2026, 6:45 AM EDT - 14 days ago

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

CNTA

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 15 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK NVO PFE PPH

Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership

Mar 30, 2026, 10:01 AM EDT - 15 days ago

Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership

Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Mar 30, 2026, 9:17 AM EDT - 15 days ago

Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery

Mar 30, 2026, 8:24 AM EDT - 15 days ago

Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery

Eli Lilly inks $2.75B AI deal with Insilico, bets on China biotech

Mar 30, 2026, 3:54 AM EDT - 15 days ago

Eli Lilly inks $2.75B AI deal with Insilico, bets on China biotech

Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports

Mar 30, 2026, 12:49 AM EDT - 15 days ago

Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports

howardlindzon
howardlindzon Apr. 14 at 3:24 PM
$LLY GLP's are just a miracle ...hope It stays that way
0 · Reply
EdwardGonza
EdwardGonza Apr. 14 at 2:56 PM
$AMZN $MRK $VOYG $LLY $NVO | AWS launches Amazon Bio Discovery, a no code AI platform for drug dev. Bayer and MSK are already using it to cut antibody design from 1 year to weeks. Amazon is now the primary compute layer for the $200B AI driven pharmaceutical pipeline.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 14 at 2:42 PM
$LEXX $LLY just bout a biotech for $300M. Eli Lilly has agreed to pay up to $300 million for pre-clinical biotechnology company CrossBridge Bio in a deal that bolsters the drugmaker's cancer pipeline. The purchase price includes an undisclosed upfront payment, along with a potential milestone payment, CrossBridge said Tuesday. Houston -based CrossBridge is developing dual-payload antibody-drug conjugates, or ADCs, with its lead candidate expected to enter clinical studies later this year. THIS CAN HAPPEN TO $LEXX IN THE BLINK OF ANY EYE, BUT IMO HECK OF ALOT MORE THAN $300M. Even $300M buyout would put the price 15X from here valuation wise. Do the math.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 14 at 2:25 PM
$LEXX there is no resistance, charts dont mean anything. When positive news hits this runs faster than a gazelle. Also, did you see the news from FDA regulatory update this morning on $NVO $LLY ******The FDA just confirmed the exact weakness Lexaria is trying to fix. Clock is ticking. ⏰ Important regulatory update for Lilly’s new obesity pill Foundayo. According to an FDA letter, Eli Lilly has been asked to provide additional post-marketing safety data, including further assessment of potential liver injury. The FDA is also requiring studies on: • cardiovascular risk • delayed gastric emptying • drug levels in breast milk during lactation This does not change the approval status, but it means the safety profile will remain under close regulatory review as the launch continues.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 14 at 2:01 PM
Eli Lilly To Acquire CrossBridge Bio To Advance Dual-Payload Cancer Drugs $LLY https://stocktwits.com/news/equity/markets/eli-lilly-to-acquire-crossbridge-bio/cZJq4CiRIHo
0 · Reply
moneybag888
moneybag888 Apr. 14 at 1:58 PM
$MGTX $LLY we need volume please $ROOT $CAR $GSAT
0 · Reply
TrustButVerifi
TrustButVerifi Apr. 14 at 1:56 PM
$VKTX Maybe now that NVO partnered with OpenAi, artificial intelligence will prevail over Stupidity and they pay $40 Billion for VKTX not to lose $400 Billion! smh! $LLY $NVO
0 · Reply
mbar5
mbar5 Apr. 14 at 1:30 PM
$LLY going down hard today
0 · Reply
wwmeinc
wwmeinc Apr. 14 at 1:23 PM
$VKTX $LLY $NVO $JNJ $ABBV ......KLRA's S-1 released...looking for a $14-$16 IPO price but not set in stone yet...14 M shares maybe...or more...looks like they are planning on this upcoming Friday as a trading start...money coming to our sector.....helps in keeping our name on top to my eyes....but that is just my opinion...glta https://www.iposcoop.com/the-ipo-buzz-obesity-focused-kailera-therapeutics-sets-500-million-ipo/
1 · Reply
dewmoore
dewmoore Apr. 14 at 12:41 PM
$SLS MUST READ: The year-long "Cancer Calculus" investigation was a year-long investigation ( 124 journalists 48 newsrooms 37 countries. It's the ultimate $SLS bull case. It exposes $MRK 's DESPERATION & patent games (1,212 patent applications) designed to keep prices high. Merck needs $SLS and fresh PATENTS to survive—or $LLY or $PFE will buy $SLS to end $MRK $31B in revenue. A buyer like $LLY or $PFE could create a NEW Super-Drug patent by COMBINING $SLS proprietary assets with GENERIC Keytruda in 2028 LEGALLY BLOCKING generic rivals from the BEST cocktails. Trump & RFK Jr. want cost-effective cures. Vaccines like GPS are the answer. With $SLS- 009 targeting 20+ mutations where blockbusters fail, the urgency is at an all-time high. A bidding war is the only logical conclusion. A $31B valuation for $SLS (matching Keytruda's annual haul) puts the stock at $172.67/share. Spending $31B to protect a $300B revenue stream over 10 years is "SMART as F*CK" https://www.icij.org/investigations/cancer-calculus/merck-keytruda-cancer-drug-price/
0 · Reply
Flabslab
Flabslab Apr. 14 at 11:27 AM
$LLY NVO & HIMS up 3%. This stock....red again!
0 · Reply
notreload_ai
notreload_ai Apr. 14 at 11:24 AM
$NVO teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like $LLY https://notreload.xyz/xy/novo-teams-up-with-openai-to-supercharge-medicines/
0 · Reply
Robert121212
Robert121212 Apr. 14 at 11:23 AM
$LLY great company can’t get higher…. sure it’s 1200 in a year or 2 but I can’t wait. Anyone think we get past 1000 soon . Too crowded too much too fast ?
0 · Reply
Bazzzigar
Bazzzigar Apr. 14 at 10:51 AM
$LLY NVO HIMS
0 · Reply
StockMacroView
StockMacroView Apr. 14 at 9:19 AM
Novo Nordisk ($NVO) is partnering with OpenAI to turn AI into a company-wide productivity weapon to better compete against $LLY. The deal spans R&D to supply chain, targeting full integration by late 2026. The Take: Bullish long-term. AI isn't a magic pill for new drugs, but it provides essential "speed." In the competitive obesity market, AI-driven efficiency in data analysis and manufacturing is a major advantage. Caveat: AI’s ability to discover new molecules is still unproven. This is an "input" story focused on execution rather than guaranteed "output" or immediate revenue. Impact: The goal is to "supercharge" rather than replace staff, using AI literacy to curb hiring and improve discipline. Verdict: This strengthens Novo’s moat. AI won't save a weak pipeline, but it makes a strong company much harder to outrun. 👉Click to view @StockMacroView for timely updates amid the volatility.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 14 at 9:02 AM
Novo Nordisk Stock Up Over 2% Premarket Today — Thanks To OpenAI Tie-Up $NVO $OPENAI $LLY https://stocktwits.com/news/equity/markets/novo-nordisk-stock-up-premarket-thanks-to-openai-deal/cZJpC6HRIH9
0 · Reply
DynamicPosition
DynamicPosition Apr. 14 at 8:38 AM
The GLP-1 market is approaching its first real economic stress test, a pivotal moment for $NVO and $LLY. Obesity drugs have shifted from traditional pharma reimbursement to a consumer spending category. Key risks include high out-of-pocket costs, high first-year discontinuation rates, and fragile demand if household budgets tighten. As consumers potentially trade down to lower-cost pills or compounded alternatives, existing pricing pressures will likely intensify. This is no longer just a clinical battle—it’s a fight for "share of wallet" in a tightening economy.
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 8:01 AM
🐉 $LLY PUT — DragonAlgo® Signal Contract: LLY PUT Expiry: 2026-04-17 | Strike: $930.00 | Type: PUT Option Plan (premium): Entry: $14.44 Stop: $10.40 TP1: $18.77 TP2: $24.55 TP3: $34.66 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
BioRich
BioRich Apr. 14 at 4:08 AM
$ALT Always find it funny when newer Bulls unknowingly debunk the old pumper Bulls pumps. AUD? C'mon, we already know it's DOA. And the $ALT Bulls highlighting the success of $LLY and their AUD program (which is ahead of $ALT's) is priceless. Great information, so thank you, but kinda casts more doubt amongst the Bull ranks of $ALT's potential for success. The hits keep coming $ALT Nation.
1 · Reply
DwigtMcDichael
DwigtMcDichael Apr. 13 at 10:28 PM
$ABVE $LLY $SYRE boo you. Go beyond the UC and look at what makes $SYRE unique. $100 in 2-3 months IMO
0 · Reply
Realtrader77
Realtrader77 Apr. 13 at 9:02 PM
$SYRE it’s not niche. $ABVE and $LLY have FDA approved drugs for ulcer colitis. It will be tough to break that market and results not greater compared to approved drugs. So be careful. One drug company and not even approved. 5b$ market cap is too much. They will offer and risk is high at this point. CEO sold 2 weeks back tons of stocks.
1 · Reply
The__short_squeezer
The__short_squeezer Apr. 13 at 8:59 PM
$V $KO $MCD $LLY $AVGO There was a lot of pessimism at the beginning of the day, but the market ended with gains for both SPY and NDX. Trump proved that the naval blockade he imposed on Iran was the right thing to do, and the smart money showed that it supported his decision because this naval blockade will force Iran to surrender to him if it does not want to collapse economically.
0 · Reply